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Background: Currently it has been shown that botulinum toxin is effective for a wide variety of medical condi-
tions, and can be applied for therapeutic purposes as cosmetic. In recent years, there has been a growing trend in 
the use of this drug substance to control the muscular overactivity of bruxism. The objective of this study was the 
use of botulinum toxin type A (BTX-A) than traditional methods, by conducting a systematic review of random-
ized clinical trials (RCTs) published in the health sciences literature.
Material and Methods: An electronic search was made in the databases of the PubMed, Cochrane Library and 
Scopus data between March and October 2017, ECA, which will analyze the effect of botulinum toxin in the treat-
ment of bruxism. We included studies of bruxist patients older than 18 years where BTX-A tests were performed 
on the masseter and / or temporal muscles and the control systems were injections of placebo (saline) or the use 
of traditional methods for the treatment of bruxism. such as occlusal splints, other medications or cognitive-
behavioral therapy.
Results: Of the 68 studies identified, 4 RCTs that fit our inclusion criteria were selected. These studies show that 
BTX-A injections can reduce the frequency of bruxism episodes, decrease pain levels and maximum occlusal 
force generated by this pathology, offer superior efficacy in the treatment of bruxism compared to control groups 
who were treated with placebo or with traditional methods for the treatment of bruxism.
Conclusion: Infiltrations with BTX-A are a safe and effective treatment for patients with bruxism, so its use is 
justified in daily clinical practice, especially in patients diagnosed with severe bruxism.
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Introduction
Bruxism is a repetitive activity of the masticatory mus-
cles characterized by tightening or grinding of the teeth 
and which may have two distinct manifestations: sleep 
bruxism (SB) or awake bruxism (AB) (1). It is a common 
condition with an adult prevalence ranging between 8 
and 31% (2) and which has acquired considerable clini-
cal relevance due to its association with tooth abrasions 
and mobility, fracture of dental restorations, hypertro-
phy of the masseter muscle and myalgia or arthralgia 
characteristic of temporomandibular disorders (TMD), 
among other signs and symptoms (3-5). Although etio-
logical factors have been proposed, such as emotional 
stress, neurological disorders, certain drugs and occlu-
sal interferences (6,7), the etiology and pathophysiology 
of bruxism are still unclear, although it seems to have a 
multifactorial origin mediated by nervous systems: cen-
tral and autonomous (8,9).
Various modalities of treatment for the management 
of bruxism have been investigated, such as: occlusal 
splints, drugs such as benzodiazepine or L-dopa and 
cognitive-behavioral therapy, but they have not been 
shown to be completely effective, since their effect does 
not seem to solve the cause of it and serves mainly for 
the management of the signs and symptoms of patients, 
helping to limit the destructive effects of bruxism on 
anatomical structures (10,11).
At present, it has been shown that botulinum toxin is 
effective for a wide variety of medical pathologies, used 
both for its therapeutic effect and for aesthetic medi-
cine; It is a neurotoxin produced by a Gram-positive 
aerobic bacterium called Clostridium botulinum. There 
are seven different types of exotoxins, botulinum toxin 
type A (BTX-A) is a biological variant that temporar-
ily inhibits skeletal muscle by hindering the production 
of acetylcholine and inactivating calcium channels in 
nerve endings. In recent years, there has been an in-
creasing trend in the use of this drug to control the ac-
tivity of bruxism (12).
The aim of this study is included in the following PICO 
question: in bruxist patients, is the use of BTX-A more 
effective than the traditional methods used up to now 
on the signs and symptoms of bruxism? To answer this 
question, a systematic review of randomized clinical 
trials (RCTs) found in the health sciences literature was 
conducted.
Material and Methods
The planning and preparation of this study has followed 
the guidelines established by the PRISMA declaration 
(13) for the preparation of systematic reviews and meta-
analysis.
-Eligibility criteria
We included randomized controlled clinical trials 
(RCTs) involving bruxist patients older than 18 years in 
which the effect of botulinum toxin in the treatment of 
bruxism compared with traditional therapy is analyzed. 
Studies in which bruxism was caused by psychologi-
cal or neurological disorders and those who used this 
therapy aimed at the treatment of other diseases were 
excluded.
The test interventions were injections of botulinum 
toxin type A (BTX-A) in the masseter and/or temporal 
muscles and the control interventions were injections 
of placebo (saline solution) or the use of traditional 
methods for the treatment of bruxism such as occlusal 
splints, medications or cognitive-behavioral therapy.
-Search strategy
A search of articles was carried out in the PubMed, Co-
chrane Library and Scopus databases between March 
and October 2017, using the keywords “bruxism” and 
“botulinum toxins” combined with the Boolean opera-
tor “AND” to obtain the articles that included the search 
terms used (“bruxism” [MeSH Terms] AND “botuli-
num toxins” [MeSH Terms]) in all databases.
-Study selection
Studies that were published in English from 2007 to 
2017 and that included at least 10 patients were select-
ed. Case series and animal studies were excluded. The 
selection of the articles was carried out by consensus 
between two of the authors (TFN and SAM) based on 
the inclusion and exclusion criteria established. Their 
level of scientific evidence was also taken into account 
according to the principles of the SIGN (Scottish Inter-
collegiate Guidelines Network) (14) and only articles 
classified in the first two levels were selected (meta-
analysis, systematic reviews of clinical trials and high-
quality clinical trials with very low or low risk of bias) 
and studies of low evidence were discarded.
-Risk of bias in individual studies 
To evaluate the reliability of the results of the selected 
studies, the Cochrane criteria for the risk assessment of 
bias (version 5.1.0) (15) were used, through which the 
following was analyzed: sequence generation, alloca-
tion concealment, blinding of participants, incomplete 
outcome data, selective outcome reporting, as well as 
other possible sources of bias such as conflict of inter-
ests, in each of the included studies.
-Statistical analysis
A meta-analysis will be implemented if the results of the 
studies are comparable, that is, when the same outcome 
variables were measured with a similar technique. 
                         
Results
-Study selection and description 
In the initial search, a total of 68 articles were obtained; 
5 in PubMed, 4 in Cochrane Library and 59 in Scopus, 
of which 4 studies met our inclusion criteria as reflected 
in the PRISMA flow chart (Fig. 1). These studies were 
classified according to their level of scientific evidence 
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Fig. 1. Flow chart of the article. Selection process for the systematic review, according to PRISMA guidelines (13).
and grade of recommendation using the SIGN (Scottish 
Intercollegiate Guidelines Network) guidelines. Two of 
the studies (16,17) showed a level of evidence 1- because 
it has a high risk of bias; On the other hand, the other 
two (18,19) showed a level of scientific evidence 1+ and 
a grade of recommendation B.
The main characteristics of the studies included in the 
present systematic review are shown in Table 1.
Lee et al. (18) performed a nocturnal electromyographic 
recording of the masseter and temporal muscles in 12 
patients with bruxism, six of them received infiltrations 
of 80 IU of BTX-A (Dysport®, Ipsen Pharma, Wrex-
ham, United Kingdom) distributed in three points of 
both masseter muscles, and the other six an equivalent 
amount of saline. The patients who received BTX-A re-
ported a clinical improvement of the pathology; it was 
observed that the number of bruxism events decreased 
significantly after the injection of botulinum toxin in 
the masseter muscle but not in the temporalis muscle, 
without differing in the three post-injection times. Re-
garding the bruxism symptoms questionnaire data, the 
score decreased after the intervention in both the BTX-
A and in the saline injection groups (Table 2).
In the study by Guarda-Nardini et al. (19) injected 30 IU 
of BTX-A (Botox®, Allergan Inc., Irvine, E.E.U.U) in 
masseter muscles and 20 IU in temporal muscles to 10 pa-
tients with myofascial pain associated with bruxism. The 
descriptive analysis of the study showed a slight increase 
in the values of the maximum unassisted and assisted 
movements of buccal, protrusive and laterotrusive open-
ing (mm) in the BTX-A group (the differences between the 
baseline and follow-up values had a tendency to increase) 
and remained unchanged in the placebo group. Regarding 
the symptoms (pain at rest and in mastication), evaluated 
by means of a visual analogue scale (VAS), they decreased 
in the BTX-A group while in the placebo group it remained 
constant, although the effectiveness of the mastication did 
not improve in neither of the two groups (Table 2). 
Al-Wayli et al. (16) compared the efficacy of treatment 
with BTX-A versus conventional treatments for brux-
ism. For this, they recruited 50 subjects diagnosed with 
nocturnal bruxism, 25 were infiltrated with 20 IU of 
BTX-A (Botox®, Allergan Inc., Irvine, USA) in three 
points of both masseters, and the other 25 were treated 
with behavioral therapy, occlusal splint and pharmaco-
logical measures (diclofenac 50 mg). In the assessment 
of pain, there were no significant differences in the 
mean preoperative pain score between the two groups, 
however, there was a relevant difference in the average 
value of postoperative pain at 3 weeks in both the BTX-
A group and in the control group that used traditional 
methods for the treatment of bruxism. From the second 
postoperative month, the mean pain score decreased 
significantly in both groups, reaching its lowest value 
at the sixth month and being much lower in the BTX-A 
group than in the control group (Table 2).
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Zhang et al. (17) recruited 30 patients with bruxism to 
assess the therapeutic efficacy of BTX-A injection in 
terms of occlusal force, biting time and symmetric dis-
tribution of occlusal force using a T-Scan. 10 patients 
were infiltrated with 25 IU/ml of BTX-A in three points 
of both masseter muscles, another 10 were infiltrated 
with saline in the same way and the remaining 10 were 
a control group without any intervention. The bite time 
in the BTX-A group was significantly longer after 
three months, and decreased after six months, but there 
were no significant changes in the placebo and control 
groups. With respect to the maximum occlusal force, 
significantly lower values were achieved in the BTX-A 
group compared to the other two groups where there 
were no relevant differences, reaching its lowest value 
after three months of treatment. There were no signifi-
cant differences between the groups in the symmetric 
distribution of the occlusal force, however, there was a 
tendency towards its improvement during the treatment 
(Table 2).
-Risk of bias assessment 
The evaluation of the risk of bias through the Cochrane 
criteria showed positive results in the generation of ran-
dom sequence, and in the absence of incomplete data 
and selective results for the four included studies, but 
in none of them, despite being RCTs , the method used 
to generate the allocation sequence and the measures 
to blind the participants and the study staff, in particu-
lar the studies of Zhang et al. (17) and Al-Wayli et al. 
(16) they do not specify that they be blinded, and in this 
last one the sample was formed entirely by women, this 
makes that these last two studies have a high risk of 
bias, and those of Lee et al. (18) and Guarda-Nardini et 
al. (19) a low risk of bias (Fig. 2).
-Data extraction: qualitative synthesis 
The results of these studies showed that BTX-A injec-
tions can reduce the frequency of bruxism episodes, 
decrease pain levels and the maximum occlusal force 
generated by this pathology, offering superior effec-
tiveness in the treatment of bruxism compared to the 
Fig. 2: Risk of bias assessment. According to the Cochrane Hand book for Systematic Reviews of Inter-
ventions, version 5.1.0 (15). +: low risk of bias; - : high risk of bias; ?: unclear risk of bias.
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control groups that were treated with placebo or with 
traditional methods for the treatment of bruxism. Of the 
four included studies, Guarda-Nardini et al. (19) and Al-
Wayli et al. (16), did not specify if the botulinum toxin 
injections had adverse effects, however Lee et al. (18) 
and Zhang et al. (17) reported the absence of such ad-
verse effects, both locally and systemically. 
-Data extraction: quantitative synthesis 
Due to the heterogeneity presented to the results of the 
different studies, since each one measures the variables 
in different ways, it is not possible to do a meta-analysis 
with the available data.
Discussion
Botulinum toxins, purified exotoxins of Clostridium 
botulinum, have been used for a long period of time 
for numerous neuromuscular disorders (20,21). These 
toxins can inhibit neuromuscular transmission, which 
justifies its clinical application in the treatment of brux-
ism, since recent scientific evidence has indicated that 
bruxism has a multifactorial etiology mediated by the 
central nervous and autonomic systems, which regulate 
the motor activity of the chewing muscles (22,23).
Currently, many authors (24-26) support the use of 
BTX-A for the treatment of various conditions of the 
oral-maxillofacial region based on the positive results 
obtained in various clinical trials collected in the litera-
ture. Rao et al. (24) made a review showing the results 
of several clinical trials and case reports that supported 
the use of BTX-A for the treatment of TMD, gingi-
val smile correction, muscle hypertrophy and spasms, 
headache (migraine), trigeminal neuralgia and even af-
ter the placement of dental implants. They noted that 
although BTX-A could decrease muscle strength and 
mastication, it is temporary and normal function would 
return when the effect of the toxin disappeared. Gay-
Escoda et al. (25) conducted a review of the literature 
that included clinical trials in which BTX-A was used 
in the salivary glands for the treatment of sialorrhea 
derived from different neurological disorders such as 
infantile cerebral palsy, the disease of Parkinson’s and 
amyotrophic lateral sclerosis. More than half of the au-
thors injected the product into the parotid glands, 9.5% 
in the submaxillary glands and 38% in both. The to-
tal doses of toxin injected varied from 10 to 100 IU of 
Botox® or 30 to 450 IU of Dysport® according to the 
different authors. A reduction in saliva production was 
observed after these injections, and the duration of the 
therapeutic effect was 1.5-6 months. Six articles (30%) 
described the presence of adverse effects such as dys-
phagia, xerostomia and difficulties to chew. The authors 
concluded that the injection of BTX-A in the salivary 
glands may be a valid treatment option in patients with 
sialorrhea, since it is able to improve the quality of life, 
however, it is important to be aware that the duration of 
the therapeutic effect is limited in time and usually lasts 
a few months. In a retrospective study carried out by 
Alonso-Navarro et al. (26), the evolution of 19 patients 
with severe bruxism who were treated periodically with 
infiltrations of BTX-A in both temporal and masseter 
muscles, using initial doses of 25 IU per muscle, dur-
ing follow-up periods of 0.5 to 11 was described; the 
doses were adjusted throughout the follow-up according 
to the degree of response observed. None of the patients 
presented side effects. The final dose ranges reached 
ranged from 25 to 40 IU per muscle and the duration of 
the effects ranged from 13 to 26 weeks. Based on these 
results, they concluded that infiltrations with BTX-A 
are a safe and effective treatment for patients with se-
vere bruxism. The four studies that we have selected 
for the review showed that BTX-A injections can reduce 
the frequency of bruxism episodes, decrease pain levels 
and the maximum occlusal force generated by this pa-
thology, offering more satisfactory clinical results in the 
treatment of bruxism compared to control groups that 
were treated with placebo or traditional methods, thus 
reiterating that the use of BTX-A is an effective alterna-
tive in the treatment of this pathology.
Psychological factors play a very important role both in 
the etiology and in the treatment of bruxism (27). This 
aspect is reflected in the results of the study by Zhang et 
al. (17), since the values of maximum masticatory force 
had been reduced, although to different degrees, both 
in the BTX-A experimental group, and in the placebo 
and control groups without intervention. This change in 
biting force in the placebo and control groups indicates 
that psychological intervention can play an important 
role in the treatment of bruxism.
The effect of the BTX-A is transient and is largely lim-
ited to the injection area. A review by Ihde and Kon-
stantinovic (28) has indicated that the most common 
adverse effects of BTX-A are local, such as sensitivity 
and mild cutaneous reaction at the site of injection, sys-
temic effects, such as headache and nervous atrophy. 
reversible, and specific effects, including dysphonia, 
dysphagia and dry mouth. However, of the four stud-
ies included in the review, only two (Lee et al. (18) and 
Zhang et al. (17)) reported the absence of adverse ef-
fects at the time of treatment, but none of them report-
ed the possible adverse effects after the injection. Tan 
and cols. (29) and Monroy et al. (30) have explained in 
their studies that the use of BTX-A in the treatment of 
bruxism can cause dysphagia or mild pain at the site 
of injection and temporary drooling, however, patients 
who suffered these adverse effects received a large dos-
age (> 100 IU) or had a condition complicated by other 
medical conditions. In none of the four studies we have 
selected exceeds the total dose of 100 IU, therefore, in-
jections of BTX-A at a dose lower than 100 IU in the 
masseter or temporal muscles in patients who are other-
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wise healthy are safe, its use being feasible in the usual 
clinical practice.
The results of the present review showed that injections 
of BTX-A in the masseter and/or temporal muscles can 
be a valid treatment option in patients with bruxism, 
since they can improve the quality of life. However, it is 
not exempt from limitations, since most of the samples 
are too small to allow obtaining statistically significant 
results. Furthermore, in none of the included studies, 
despite being randomized clinical trials, the method 
used to generate the allocation sequence is described, 
nor are the measures to blind the participants and the 
study staff, in fact, in two of the studies do not speci-
fy that they be blinded and in one of them the sample 
completely lacked homogeneity since it was completely 
made up of women. To all this, it must be added that in 
all the studies except one, the follow-up period for the 
patients was less than one year, which makes the need 
for long-term controlled studies that allow us to assess 
both the therapeutic effect indispensable. as the adverse 
effects of this treatment over the years.
Conclusions
In conclusion, the infiltrations of BTX-A can reduce the 
frequency of bruxism episodes, as well as the mastica-
tory force, and decrease the levels of pain derived from 
it, which translates into an improvement in the quality 
of life of patients. In addition, in doses <100UI it is a 
safe treatment with a low probability of adverse ef-
fects occurring in healthy patients. Therefore, the use 
of BTX-A is a safe and effective treatment for patients 
with bruxism that shows better clinical results than 
traditional methods such as occlusal splints, drugs or 
cognitive-behavioral therapy, so its use would be justi-
fied in daily clinical practice, especially in patients di-
agnosed with severe bruxism.
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